Fresh Frozen Plasma in Liver Failure

Prophylactic FFP for Procedures: Not Recommended

• The European Association for the Study of the Liver (EASL) provides a strong recommendation against using FFP to correct prolonged INR before invasive procedures in cirrhotic patients, as it does not reduce bleeding risk and carries significant potential harms, including increased portal pressure, volume overload, and transfusion-related complications 1, 2
• FFP contains both procoagulant and anticoagulant proteins in balanced proportions, so transfusion frequently fails to normalize prothrombin time in cirrhotic patients, with ex vivo studies demonstrating FFP only minimally improves thrombin generation capacity in liver disease, and actually worsened hemostatic capacity in one-third of patients 1, 3, 4
• A Cochrane review found no studies demonstrating efficacy of prophylactic FFP in preventing bleeding during procedures in cirrhotic patients, and INR is a poor predictor of bleeding risk in liver disease, as it only measures select procoagulant factors and ignores anticoagulant proteins 1, 2, 4

Significant Risks of FFP in Liver Disease

• FFP transfusion carries potentially life-threatening complications that are particularly problematic in cirrhotic patients, including increased portal pressure from volume expansion, paradoxically increasing bleeding risk, transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO) with 5-15% mortality rate, allergic/anaphylactic reactions, infection transmission, hemolytic reactions, and red cell alloimmunization 1, 2, 3, 4, 5

When FFP IS Indicated in Liver Disease

• FFP has a role in active major bleeding when administered in balanced ratios with red blood cells (typically 1:1 or 1:1.5 ratio) until coagulation test results are available, and may be appropriate for disseminated intravascular coagulation (DIC) with active bleeding or high bleeding risk, warfarin reversal in active bleeding when prothrombin complex concentrates unavailable, and thrombotic thrombocytopenic purpura as replacement fluid during apheresis 6
• When FFP is genuinely indicated, the therapeutic dose is 15 ml/kg to achieve minimum 30% factor concentration 6, 7

Alternative Approaches

• No routine correction needed for most procedures, as technical factors and liver disease complications predict bleeding better than coagulation tests, and consider viscoelastic testing (TEG/ROTEM) to guide management rather than INR 1, 4
• Prothrombin complex concentrates (PCCs) may be more effective than FFP for correcting PT/INR, though evidence is limited, and fibrinogen concentrate or cryoprecipitate for documented hypofibrinogenemia 3, 6

Critical Clinical Pitfalls

• Do not use INR alone to guide transfusion decisions in liver disease—it does not reflect true hemostatic balance, and avoid prophylactic FFP simply because laboratory values are abnormal without bleeding 1, 6, 7
• Do not use FFP for volume expansion—crystalloids or colloids are appropriate, and recognize that elevated INR in liver disease represents rebalanced hemostasis, not simply deficiency 1, 2, 6, 7

Management of Coagulopathy in Cirrhotic Patients Before Emergency Laparotomy

Critical Context and Recommendations

• The European Association for the Study of the Liver (EASL) and American Gastroenterological Association (AGA) guidelines recommend against routine use of fresh frozen plasma (FFP) in stable cirrhotic patients undergoing common gastrointestinal procedures, but this patient requires urgent/emergency laparotomy for a perforated peptic ulcer, which falls outside the scope of those guideline recommendations 8, 9, 10.
• The EASL guidelines state that for high-risk procedures, platelet transfusion should be considered only when counts are <20 × 10^9/L (strongly considered) or between 20-50 × 10^9/L (case-by-case basis), and this patient's platelet count of 90 × 10^9/L does not meet criteria for urgent transfusion before addressing coagulopathy 8, 9.
• The AGA guidelines note that "in patients with severe derangements in coagulation or thrombocytopenia undergoing a procedure that is high risk for bleeding, decisions about prophylactic blood transfusions should include discussions about potential benefits and risks" 9, 10.

Rationale for FFP in Emergency Setting

• Emergency laparotomy for perforation represents a high-risk bleeding scenario where local hemostasis may be difficult, and FFP has a role when administered in balanced ratios with red blood cells until coagulation results are available 11.
• The patient's INR of 2.0 with urgent surgery creates a clinical scenario where some correction may be attempted despite guideline recommendations against routine use, and FFP provides multiple coagulation factors that may be deficient in cirrhosis 8.

Limitations and Caveats

• The evidence for FFP use in cirrhotic patients undergoing emergency major surgery is based on very low certainty evidence, and no RCTs exist comparing FFP versus no FFP in this setting 9, 10.
• The American Gastroenterological Association (AGA) guidelines recommend considering consultation with hematology for complex coagulopathy management in high-risk scenarios 9, 10.
• The European Association for the Study of the Liver (EASL) guidelines state that INR is a poor predictor of bleeding risk in liver disease, as it only measures select procoagulant factors, and other factors such as fibrinogen level should be considered 8.

Emergency Hemostatic Management in Cirrhosis

Guideline Recommendations on Fresh Frozen Plasma

Limitations of Conventional Coagulation Testing

Risks Associated with Fresh Frozen Plasma Transfusion

Alternative Hemostatic Strategies

ASA Guidelines for Managing Coagulopathy in Cirrhotic Patients Undergoing Emergency Laparotomy

Indications for Fresh Frozen Plasma (FFP)

• The American Society of Anesthesiologists (ASA) recommends administering FFP to correct coagulopathy when the INR exceeds 2.0 in patients who are bleeding or require urgent surgery, such as emergency laparotomy for perforated ulcer. 16

Dosage Recommendations

• ASA guidance advises a therapeutic FFP dose of 10–15 mL /kg to achieve at least 30 % plasma factor concentration, which corresponds to roughly 3–4 units for an average adult. 16

Platelet Transfusion Thresholds

• According to ASA guidelines, platelet transfusion is not indicated for surgical patients when the platelet count is > 50 × 10⁹/L and platelet function is normal. 16

Cryoprecipitate Use

• Cryoprecipitate should be given only when a hypofibrinogenemia is documented (fibrinogen < 80–100 mg/dL) in the setting of active bleeding. 17
• Cryoprecipitate does not correct the broad coagulation factor deficiencies reflected by an elevated INR/PT; it primarily supplies fibrinogen, factor VIII, von Willebrand factor, and factor XIII. 17

Practical Administration Considerations

• If time permits, obtain a fibrinogen level; a value < 1.5 g/L would justify adding cryoprecipitate to the FFP regimen. 17
• Use ABO‑compatible FFP; when the patient’s blood type is unknown, group AB plasma is acceptable. 17
• Thaw FFP rapidly—either microwave for 2–3 minutes or dry oven for ~10 minutes—and administer immediately after thawing. 17